These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Association of Time to Clinical Remission With Sustained Resolution in Children With New-Onset Infantile Spasms. Yuskaitis CJ; Mytinger JR; Baumer FM; Zhang B; Liu S; Samanta D; Hussain SA; Yozawitz EG; Keator CG; Joshi C; Singh RK; Bhatia S; Bhalla S; Shellhaas R; Harini C; Neurology; 2022 Nov; 99(22):e2494-e2503. PubMed ID: 36038267 [TBL] [Abstract][Full Text] [Related]
4. Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms. Askalan R; Mackay M; Brian J; Otsubo H; McDermott C; Bryson S; Boyd J; Snead C; Roberts W; Weiss S J Child Neurol; 2003 Mar; 18(3):165-70. PubMed ID: 12731640 [TBL] [Abstract][Full Text] [Related]
12. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lux AL; Edwards SW; Hancock E; Johnson AL; Kennedy CR; Newton RW; O'Callaghan FJ; Verity CM; Osborne JP; Lancet Neurol; 2005 Nov; 4(11):712-7. PubMed ID: 16239177 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcome in children with infantile spasms treated with vigabatrin: a cohort of 180 patients. Djuric M; Kravljanac R; Tadic B; Mrlješ-Popovic N; Appleton RE Epilepsia; 2014 Dec; 55(12):1918-25. PubMed ID: 25377998 [TBL] [Abstract][Full Text] [Related]
14. Adrenocorticotropic hormone versus prednisolone in the treatment of infantile spasms post vigabatrin failure. Jones K; Snead OC; Boyd J; Go C J Child Neurol; 2015 Apr; 30(5):595-600. PubMed ID: 24965788 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of vigabatrin in Japanese patients with infantile spasms: Primary short-term study and extension study. Ohtsuka Y Epilepsy Behav; 2018 Jan; 78():134-141. PubMed ID: 29190579 [TBL] [Abstract][Full Text] [Related]
16. Infantile Spasms-Have We Made Progress? Kelley SA; Knupp KG Curr Neurol Neurosci Rep; 2018 Apr; 18(5):27. PubMed ID: 29671077 [TBL] [Abstract][Full Text] [Related]
17. A risk-benefit assessment of treatments for infantile spasms. Nabbout R Drug Saf; 2001; 24(11):813-28. PubMed ID: 11665869 [TBL] [Abstract][Full Text] [Related]
18. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Mackay MT; Weiss SK; Adams-Webber T; Ashwal S; Stephens D; Ballaban-Gill K; Baram TZ; Duchowny M; Hirtz D; Pellock JM; Shields WD; Shinnar S; Wyllie E; Snead OC; ; Neurology; 2004 May; 62(10):1668-81. PubMed ID: 15159460 [TBL] [Abstract][Full Text] [Related]
19. Clinical profile and treatment of infantile spasms using vigabatrin and ACTH--a developing country perspective. Ibrahim S; Gulab S; Ishaque S; Saleem T BMC Pediatr; 2010 Jan; 10():1. PubMed ID: 20078871 [TBL] [Abstract][Full Text] [Related]
20. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. O'Callaghan FJ; Lux AL; Darke K; Edwards SW; Hancock E; Johnson AL; Kennedy CR; Newton RW; Verity CM; Osborne JP Epilepsia; 2011 Jul; 52(7):1359-64. PubMed ID: 21668442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]